Thus, future studies need to [1] evaluate whether novel TAS1R3 agonists or genetic enrichment strategies can reverse skeletal muscle insulin resistance; and [2] develop skeletal muscle-specific, inducible TAS1R3 overexpression models to assess the potential benefits of TAS1R3 enrichment on primary insulin resistance and secondary muscle pathologies associated with T2D. Here, TAS1R3 is linked to Insulin resistance.